Calgent Biotechnology Co., Ltd
Founded in 2019, this biotechnology company develops novel oncology and immunology therapies with an integrated R&D platform spanning translational research, pharmacology, formulation/CMC, and clinical development. The company advances first-in-class small molecules and biologics (including single-domain antibody formats), pursues regulatory filings (FDA/TFDA) for clinical studies, and combines proprietary programs with strategic in-licensing and partnerships.
Industries
Nr. of Employees
small (1-50)
Calgent Biotechnology Co., Ltd
24F., No. 1, Songzhi Rd., Xinyi Dist., Taipei City 11047, Taiwan (R.O.C.)
Patents
Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
US-12453708-B2
View DetailsAminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US-11919858-B2
View DetailsAminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
US-11833122-B2
View DetailsCompounds and pharmaceutical composition associated with ubiquitination-proteasome system
US-11084786-B2
View DetailsCompounds and pharmaceutical composition associated with ubiquitination-proteasome system
US-10745350-B2
View DetailsAminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US-10577328-B2
View Details
Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
US-12453708-B2
View DetailsAminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US-11919858-B2
View DetailsAminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
US-11833122-B2
View DetailsCompounds and pharmaceutical composition associated with ubiquitination-proteasome system
US-11084786-B2
View DetailsCompounds and pharmaceutical composition associated with ubiquitination-proteasome system
US-10745350-B2
View DetailsAminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
US-10577328-B2
View DetailsProducts
Hectinib
Oral HECT-domain E3 ubiquitin ligase inhibitor in development for multiple myeloma; designated as an orphan drug by the US FDA.
Fiberfate
Oral HECT-domain E3 ubiquitin ligase inhibitor being developed to suppress TGF-β–driven profibrogenic signaling for progressive pulmonary fibrosis.
CAL010
First-in-class fat reduction agent that selectively reduces adipocytes and target adipose tissue mass; under development for local and systemic adipose reduction.
CAL005
Preclinical humanized single-domain antibody therapeutic designed to neutralize multiple ELR+ CXC chemokines to suppress neutrophil recruitment and activation in neutrophil-mediated inflammatory diseases such as IBD.
Hectinib
Oral HECT-domain E3 ubiquitin ligase inhibitor in development for multiple myeloma; designated as an orphan drug by the US FDA.
Fiberfate
Oral HECT-domain E3 ubiquitin ligase inhibitor being developed to suppress TGF-β–driven profibrogenic signaling for progressive pulmonary fibrosis.
CAL010
First-in-class fat reduction agent that selectively reduces adipocytes and target adipose tissue mass; under development for local and systemic adipose reduction.
CAL005
Preclinical humanized single-domain antibody therapeutic designed to neutralize multiple ELR+ CXC chemokines to suppress neutrophil recruitment and activation in neutrophil-mediated inflammatory diseases such as IBD.
Expertise Areas
- Translational research
- Preclinical pharmacology and toxicology
- Small-molecule drug discovery
- Biologic (nanobody) therapeutic development
Key Technologies
- First-in-class small-molecule discovery
- Single-domain antibody (nanobody) therapeutics
- E3 ubiquitin ligase inhibition
- Oral delivery platforms for proteins
News & Updates
US FDA granted approval to conduct a Phase I clinical trial (IND) for CAL056 mesylate; trial locations include Texas and California.
The US FDA granted orphan drug designation for CAL056 mesylate.
Taiwan FDA (TFDA) provided approval for multi-center Phase I clinical trials for CAL056 mesylate to be conducted in the US and Taiwan.
Formal establishment of a translational research center to support project development and operations.
Participation in the BIO International Convention (San Diego) to present R&D programs to international partners.
US FDA granted approval to conduct a Phase I clinical trial (IND) for CAL056 mesylate; trial locations include Texas and California.
The US FDA granted orphan drug designation for CAL056 mesylate.
Taiwan FDA (TFDA) provided approval for multi-center Phase I clinical trials for CAL056 mesylate to be conducted in the US and Taiwan.
Formal establishment of a translational research center to support project development and operations.
Participation in the BIO International Convention (San Diego) to present R&D programs to international partners.